SG11201803519YA - A solid state form of pladienolide pyridine compounds and methods of use - Google Patents
A solid state form of pladienolide pyridine compounds and methods of useInfo
- Publication number
- SG11201803519YA SG11201803519YA SG11201803519YA SG11201803519YA SG11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA
- Authority
- SG
- Singapore
- Prior art keywords
- tsukuba
- eisai
- tokodai
- shi
- rearch
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 150000003222 pyridines Chemical class 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000001324 spliceosome Anatomy 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (fr) | 2015-11-18 | 2016-11-17 | Forme d'état solide de composés de pladiénolide-pyridine et procédés pour leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803519YA true SG11201803519YA (en) | 2018-06-28 |
Family
ID=57472076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803519YA SG11201803519YA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
| SG10201913045PA SG10201913045PA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913045PA SG10201913045PA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (fr) |
| EP (1) | EP3377485B1 (fr) |
| JP (2) | JP6312282B2 (fr) |
| KR (1) | KR20180083376A (fr) |
| CN (1) | CN108473479B (fr) |
| AU (2) | AU2016357433B2 (fr) |
| BR (1) | BR112018009995B1 (fr) |
| CA (1) | CA3004623C (fr) |
| ES (1) | ES2757174T3 (fr) |
| IL (1) | IL259198B2 (fr) |
| MD (1) | MD3377485T2 (fr) |
| MX (2) | MX2018006155A (fr) |
| RU (2) | RU2021102393A (fr) |
| SG (2) | SG11201803519YA (fr) |
| WO (1) | WO2017087667A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201945351A (zh) * | 2018-04-09 | 2019-12-01 | 日商衛材R&D企管股份有限公司 | 特定普拉二烯內酯化合物及其使用方法 |
| AU2019252432B2 (en) | 2018-04-12 | 2023-04-13 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| AU2019279012A1 (en) * | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| US20230022489A1 (en) * | 2019-12-04 | 2023-01-26 | Athma A. PAI | Identifying non-productive splice sites |
| AR122546A1 (es) * | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (fr) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| CN1671856B (zh) | 2002-07-31 | 2010-05-12 | 卫材R&D管理株式会社 | 生理活性物质 |
| EP1541570A4 (fr) | 2002-07-31 | 2008-05-21 | Mercian Corp | Nouvelle substance active sur le plan physiologique |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| NZ540103A (en) | 2002-11-29 | 2007-05-31 | Mercian Corp | Process for producing macrolide compound |
| KR20060110865A (ko) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ |
| CA2552553C (fr) | 2003-11-28 | 2015-01-06 | Kanagawa Academy Of Science And Technology | Methode de detection, diagnostic et remede contre le cancer du foie |
| US20070199741A1 (en) | 2004-07-02 | 2007-08-30 | Kenji Noumi | Combined Weighing Apparatus |
| JP4599357B2 (ja) | 2004-07-20 | 2010-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| EP1935893A4 (fr) | 2005-10-13 | 2009-07-22 | Eisai R&D Man Co Ltd | Synthèse totale de pladienolide b et de pladienolide d |
| WO2008111464A1 (fr) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | Procédé pour l'examen d'une action d'un agent anti-cancéreux utilisant un défaut d'épissage en tant que mesure |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| SG11201609693XA (en) * | 2014-05-15 | 2016-12-29 | Eisai R&D Man Co Ltd | Pladienolide pyridine compounds and methods of use |
-
2016
- 2016-11-17 MX MX2018006155A patent/MX2018006155A/es unknown
- 2016-11-17 CA CA3004623A patent/CA3004623C/fr active Active
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 MX MX2021001441A patent/MX2021001441A/es unknown
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/fr active Active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/fr active Application Filing
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko not_active Application Discontinuation
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803519YA (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201811152YA (en) | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804038VA (en) | Conditionally active heterodimeric polypeptides and methods of use thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201808920RA (en) | Genome editing of human neural stem cells using nucleases | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods |